Pharma

ms-nandita-singh-editor-biospectrum-asia

Nandita Singh: Outlook positive in China despite slowdown

  • China
  • |
  • Opinion

Is China bioscience slowing down? From the numbers that have been put together by the BioSpectrum Asia Pacific Bioscience Industry Survey 2013, it does look so. However, a little deeper look clearly shows that China is not slowing down... Read more

parkinsons-disease11

Aus pharma benefit scheme includes Parkinson's drug...


  • Australia
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The Australian Pharmaceutical Benefits Scheme has listed a novel treatment for Parkinson's disease in order to... Read more

good-news-for-alzheimer-s-disease-patients-shasun-and-debiopharm-will-manufacture-brain-drug-huperzine-a

Japan approves Avastin for brain cancer treatment


  • Japan
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Roche announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Avastin (bevacizumab)... Read more

j-j-acquires-aragon-and-its-androgen-receptor-antagonist-program-including-cancer-drug-arn-509-a-second-generation-androgen-receptor-signaling-inhibitor-currently-in-phase-ii-trial

J&J to acquire cancer drug firm for $1 bn

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Johnson & Johnson is going to acquire US-based Aragon Pharmaceuticals for $650 million in cash up front along with $350 million... Read more

dr-habil-khorakiwala-chairman-wockhardt-fears-that-the-firm-may-lose-usd100-million-in-sales-due-to-the-ban-by-indian-authorities

Wockhardt chairman: Painkiller ban may cost us $100 mn

  • India
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The several bans on Proxyvon, a brand under India-based Wockhardt sold formulation of the painkiller dextropropoxyphene, has... Read more

govt-push-policies-investment

DIPP wants review of India's pharma FDI policy

  • India
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

New Delhi: Concerned over spate of acquisitions of domestic pharma firms by multinationals, India's Department of Industrial Policy and... Read more

zhejiang-medicine-will-develop-and-commercialize-ambrx-site-specific-antibody-drug-conjugate-adc-targeting-her2-positive-breast-cancer-arx788

Ambrx, Zhejiang, WuXi to develop cancer drug in China

  • China
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: US-based Ambrx and China-based Zhejiang Medicine (ZMC) announced that they have formed a collaboration to develop and commercialize... Read more

astars-genome-institute-of-singapore-gis-and-oxford-biodynamics-obd-will-use-episwitch-platform-to-differentiate-epigenetic-footprint-of-various-stem-cells-from-their-cell-lines

Prism to start PRI-724 trials to treat fibrosis

  • Japan
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Prism Pharma, a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions,... Read more

fall-from-grace-glaxosmithkline-gsk-fires-dr-jingwu-zhang-senior-vp-of-its-shanghai-r-d-unit-for-publishing-fraud-data-in-nature

GSK fires Chinese R&D head for publishing fraud data in Nature

  • China
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: GlaxoSmithKline (GSK) has fired the head of its Chinese R&D unit, Dr Jingwu Zhang, after it was found in a probe that he had... Read more

one-in-two-asian-men-could-be-at-risk-of-developing-osteoporosis-or-other-bone-related-diseases

Almost 50% Asian men at risk of bone problems

  • Singapore
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: One-in-two Asian men could be at risk of developing osteoporosis or other bone-related diseases reveals the analysed results... Read more

zydus-recalls-oversized-warfarin-tablets-lot-as-it-may-lead-to-development-of-bleeding-as-an-adverse-reaction

Zydus recalls heart drug due to ‘over-bleed’ scare

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Zydus Pharmaceuticals is voluntarily recalling one lot of Warfarin 2 mg tablets (lot number MM5767 with expiration date of June... Read more

apotex-recalls-15-lots-of-piperacillin-and-tazobactam-for-injection-on-behalf-of-hospira

VM202 trial completes patient administration

  • Korea
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: ViroMed, a leading biotechnology company, announced the final enrollment and administration of 105 patients for the company's... Read more

Previous 1 3 4 5 6 7

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X